Ranbaxy Launches Authorized Generic Version of Caduet® In the U.S.

PRINCETON, N.J. & GURGAON, India--(BUSINESS WIRE)-- Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) (“Ranbaxy”), has launched an authorized generic version of Caduet® in the U.S. market, as part of an agreement with Pfizer Inc.

Caduet® is a fixed-dose combination of Atorvastatin-Amlodipine besylate (presently marketed by Pfizer under the brand Caduet®, which also contains a crystalline form of Atorvastatin). The product is indicated for patients suffering from both, high blood pressure and high levels of cholesterol. Caduet® generated total annual sales of $339 million in the U.S. (IMS – MAT September 2011).

Ranbaxy is making available the full range of the generic version of Caduet®.

Mr. Venkat Krishnan, Sr. Vice President & Regional Director, Americas, Ranbaxy, said, “The introduction of Atorvastatin-Amlodipine besylate tablets is a significant and important addition to our portfolio of cardio-vascular products, in the U.S. The launch further complements our resolve to bring high quality, affordable generic medicines as early as possible to the U.S. healthcare system, benefitting a wider cross-section of people.”

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida U.S.A., is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company’s commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com.

* Caduet® is a registered trademark of Pfizer.



CONTACT:

Ranbaxy Pharmaceuticals Inc.
India
Ramesh Adige, +91-124-4135000
President - Corporate Affairs and
Global Corporate Communications
[email protected]
or
Raghu Kochar, +91-124-4135141
Mobile: 9811617256
Director-Corporate Communications
[email protected]
or
Krishnan Ramalingam, +91-124-4135143
Mobile: 9810042540
General Manager - Corporate Communications
[email protected]
USA
or
Chuck Caprariello, 609-720-5615
Vice President, Corporate Communications and Government Affairs
[email protected]

KEYWORDS:   United States  Asia Pacific  North America  New Jersey  India

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science

MEDIA:

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.